Table Info

Table 1.

Patient and liver tumor characteristics prior to the start of treatment

Clinical variables	Value
Number of subjects	48
Age^a [mean ± standard deviation (SD), years]	55.3 ± 18
Sex (female:male)	25:23
Number of lesions	94
KRAS positive	29/48 (60.4%)
Extrahepatic disease	23/48 (47.9%)
The median time between MRI and chemotherapy (days)	23
Local tumor progression	17/48 (35.4%)
Chemoradiotherapy	17/48 (35.4%)
Follow-up (months)	34.9 21
Location of primary tumor
Ascending colon	35/48 (72.9%)
Transverse colon	2/48 (4.2%)
Descending and sigmoid colon	11/48 (22.9%)
MSI
No testing available	30/48 (62.5%)
MSI-low (L)	17/48 (35.4%)
MSI-high (H)	1/48 (2.1%)
Tumor number
1	31/48 (64.6%)
> 1	17/48 (35.4%)
TNM classification
II or III	4/48 (8.3%)
IV	44/48 (91.7%)
Tumor size
≤ 3 cm	61/94 (64.9%)
> 3 cm	33/94 (35.1%)
Chemotherapy regimen
FOLFIRI	4/48 (8.3%)
FOLFOX	44/48 (91.7%)

^a at the time of MRI

Declarations

Author contributions

AT and DD: Conceptualization, Investigation, Validation, Writing—original draft, Writing—review & editing. BD and JN: Investigation, Writing—review & editing. MSG: Writing—review & editing, Supervision. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

This study was approved by the IRB of Massachusetts General Hospital [#2017P00004]. The research complies with the Declaration of Helsinki.

Consent to participate

The consent to participate has been waived by the IRB of Massachusetts General Hospital given the retrospective nature of this study.

Consent to publication

Not applicable.

Availability of data and materials

The datasets for this manuscript are not publicly available because data contains personally identifiable information that may be restricted from public access to protect individuals’ privacy. Requests for accessing the datasets should be directed to (Azadeh Tabari, atabari@mgh.harvard.edu).

Funding

Not applicable.

Copyright

References

Martin J, Petrillo A, Smyth EC, Shaida N, Khwaja S, Cheow HK, et al. Colorectal liver metastases: current management and future perspectives. World J Clin Oncol. 2020;11:761–808. [DOI] [PubMed] [PMC]

Chow FC, Chok KS. Colorectal liver metastases: an update on multidisciplinary approach. World J Hepatol. 2019;11:150–72. [DOI] [PubMed] [PMC]

Adam R, Kitano Y. Multidisciplinary approach of liver metastases from colorectal cancer. Ann Gastroenterol Surg. 2019;3:50–6. [DOI] [PubMed] [PMC]

Stein A, Schmoll HJ. Systemic treatment of liver metastases from colorectal cancer. Ther Adv Med Oncol. 2013;5:193–203. [DOI] [PubMed] [PMC]

Aykan NF, Özatlı T. Objective response rate assessment in oncology: current situation and future expectations. World J Clin Oncol. 2020;11:53–73. [DOI] [PubMed] [PMC]

Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1—update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132–7. [DOI] [PubMed] [PMC]

Nishino M, Jagannathan JP, Krajewski KM, O’Regan K, Hatabu H, Shapiro G, et al. Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol. 2012;198:737–45. [DOI] [PubMed] [PMC]

Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al.; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143–52. Erratum in: Lancet Oncol. 2019;20:e242. [DOI] [PubMed] [PMC]

Yirgin IK, Erturk SM, Dogan I, Vatansever S. Are radiologists ready to evaluate true response to immunotherapy? Insights Imaging. 2021;12:29. [DOI] [PubMed] [PMC]

10.

Khorrami M, Khunger M, Zagouras A, Patil P, Thawani R, Bera K, et al. Combination of peri- and intratumoral radiomic features on baseline CT scans predicts response to chemotherapy in lung adenocarcinoma. Radiol Artif Intell. 2019;1:e180012. [DOI] [PubMed] [PMC]

11.

Lee G, Park H, Lee HY, Ahn JH, Sohn I, Lee SH, et al. Tumor margin contains prognostic information: radiomic margin characteristics analysis in lung adenocarcinoma patients. Cancers (Basel). 2021;13:1676. [DOI] [PubMed] [PMC]

12.

Pérez-Morales J, Tunali I, Stringfield O, Eschrich SA, Balagurunathan Y, Gillies RJ, et al. Peritumoral and intratumoral radiomic features predict survival outcomes among patients diagnosed in lung cancer screening. Sci Rep. 2020;10:10528. [DOI] [PubMed] [PMC]

13.

Li R. Peritumoral radiomics and predicting treatment response. JAMA Netw Open. 2020;3:e2016125. [DOI] [PubMed]

14.

Sun Q, Lin X, Zhao Y, Li L, Yan K, Liang D, et al. Deep learning vs. radiomics for predicting axillary lymph node metastasis of breast cancer using ultrasound images: don’t forget the peritumoral region. Front Oncol. 2020;10:53. [DOI] [PubMed] [PMC]

15.

Daye D, Tabari A, Kim H, Chang K, Kamran SC, Hong TS, et al. Quantitative tumor heterogeneity MRI profiling improves machine learning-based prognostication in patients with metastatic colon cancer. Eur Radiol. 2021;31:5759–67. [DOI] [PubMed]

16.

Shan QY, Hu HT, Feng ST, Peng ZP, Chen SL, Zhou Q, et al. CT-based peritumoral radiomics signatures to predict early recurrence in hepatocellular carcinoma after curative tumor resection or ablation. Cancer Imaging. 2019;19:11. [DOI] [PubMed] [PMC]

17.

Nebbia G, Zhang Q, Arefan D, Zhao X, Wu S. Pre-operative microvascular invasion prediction using multi-parametric liver MRI radiomics. J Digit Imaging. 2020;33:1376–86. [DOI] [PubMed] [PMC]

18.

Song W, Yu X, Guo D, Liu H, Tang Z, Liu X, et al. MRI-based radiomics: associations with the recurrence-free survival of patients with hepatocellular carcinoma treated with conventional transcatheter arterial chemoembolization. J Magn Reson Imaging. 2020;52:461–73. [DOI] [PubMed]

19.

Yoon GY, Choi WJ, Cha JH, Shin HJ, Chae EY, Kim HH. The role of MRI and clinicopathologic features in predicting the invasive component of biopsy-confirmed ductal carcinoma in situ. BMC Med Imaging. 2020;20:95. [DOI] [PubMed] [PMC]

20.

Jiang HY, Chen J, Xia CC, Cao LK, Duan T, Song B. Noninvasive imaging of hepatocellular carcinoma: from diagnosis to prognosis. World J Gastroenterol. 2018;24:2348–62. [DOI] [PubMed] [PMC]

21.

Taghavi M, Staal F, Gomez Munoz F, Imani F, Meek DB, Simões R, et al. CT-based radiomics analysis before thermal ablation to predict local tumor progression for colorectal liver metastases. Cardiovasc Intervent Radiol. 2021;44:913–20. [DOI] [PubMed]

22.

He M, Zhang P, Ma X, He B, Fang C, Jia F. Radiomic feature-based predictive model for microvascular invasion in patients with hepatocellular carcinoma. Front Oncol. 2020;10:574228. [DOI] [PubMed] [PMC]

23.

Kim S, Shin J, Kim DY, Choi GH, Kim MJ, Choi JY. Radiomics on gadoxetic acid-enhanced magnetic resonance imaging for prediction of postoperative early and late recurrence of single hepatocellular carcinoma. Clin Cancer Res. 2019;25:3847–55. [DOI] [PubMed]

24.

Feng ST, Jia Y, Liao B, Huang B, Zhou Q, Li X, et al. Preoperative prediction of microvascular invasion in hepatocellular cancer: a radiomics model using Gd-EOB-DTPA-enhanced MRI. Eur Radiol. 2019;29:4648–59. [DOI] [PubMed]

25.

Roayaie S, Blume IN, Thung SN, Guido M, Fiel MI, Hiotis S, et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology. 2009;137:850–5. [DOI] [PubMed] [PMC]